Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.84: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026;... Read more
Sell if holding. Engine safety override at $24.84: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Mineralys Therapeutics, Inc.
Latest news
- NEWS Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Si — benzinga Jun 15, 2026 positive
- NEWS Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster — benzinga Jun 8, 2026 positive
- NEWS 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga Jun 3, 2026 neutral
- NEWS Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback — benzinga Jun 3, 2026 positive
- NEWS Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026 — benzinga May 18, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelorundrostat10-K Item 1A: 'We currently only have one product candidate, lorundrostat...Our business presently depends entirely on our ability to successfully obtain regulatory approval'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.84: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $22.49. Score 5.2/10, moderate confidence.
Take-profit target: $42.63 (+76.3% upside). Prior stop was $22.49. Stop-loss: $22.49.
Concentration risk — Pipeline: lorundrostat; Quality below floor (1.2 < 4.0).
Mineralys Therapeutics, Inc. trades at a P/E of N/A (forward -10.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover MLYS with a consensus score of 4.2/5. Average price target: $49.
What does Mineralys Therapeutics, Inc. do?Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone...
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026; no approved products and no product revenue to date.